Hemostemix (TSE:HEM) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Hemostemix Inc., a pioneering autologous stem cell therapy company, has announced a private placement aiming to raise up to $4,000,000 through the sale of Common Shares and Warrants. This strategic financing move is expected to fuel the company’s growth and advance the development and commercialization of its innovative blood-based stem cell therapeutic platform and lead product, ACP-01.
For further insights into TSE:HEM stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue